Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

VERIFY: A Comprehensive Approach to Understanding and Ending Youth E-cigarette Addiction

Led by Peter Mohler, the vice dean for research and director of the Davis Heart & Lung Research Institute at the Ohio State College of Medicine and Wexner Medical Center. This team comprised of investigators in the Colleges of Medicine, Nursing, Public Health and Engineering and the Comprehensive Cancer Center will work to provide answers about the short- and long-term health effects of e-cigarettes, including their impact on the brain, lungs, and heart; the most effective regulations to reduce the appeal and addictiveness of e-cigarettes for youth; and the best methods to help youth addicted to e-cigarettes quit.

Team VERIFY: Vaping’s End through Research and Innovation For Youth will recruit youth for a year-long study to look at the relationship between nicotine form, concentration and flavorings on youth e-cig use, addiction, neurocognitive outcomes and pulmonary health compared to healthy peers.

They will also study the influence of nicotine form, concentration and flavor on youth puffing behavior, nicotine delivery, abuse liability, toxicant exposure and acute cardiovascular and pulmonary effects; and they will develop and test a multi-point, scalable vaping cessation program to include quit-line-delivered phone counseling, text-based cessation, nicotine replacement therapy and online cessation support.

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login